Global Fragment Based Drug Discovery Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

Global Fragment Based Drug Discovery Market is Segmented By Component (Biophysical Techniques (NMR Spectroscopy, Differential Scanning Fluorimetry (DSF) Assay, Fluorescence Polarization, Isothermal Titration Calorimetry, X-ray Crystallography, Surface Plasmon Resonance (SPR), Bilayer Interferometry, Mass Spectrometry (MS), Capillary Electrophoresis, Weak Affinity Chromatography (WAC - HPLCUV/MS), Other assays (biochemical)), Non-biophysical Techniques), By Application (Oncology, Central Nervous System (CNS) Disorders, Infectious Diseases, Cardiovascular Diseases, Metabolic Disorders, Inflammation & Autoimmune Diseases), By End-user (Academic & Research Institutions, Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs), Others), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned segments.

Global Fragment Based Drug Discovery Market Size

Market Size in USD

CAGR11.6%

Study Period2024 - 2031
Base Year of Estimation2023
CAGR11.6%
Market ConcentrationHigh
Major PlayersAstex Pharmaceuticals, Beactica AB, Charles River Laboratories International, Inc., Evotec AG, Alveus Pharmaceuticals Pvt. Ltd.
*Disclaimer: Major players are listed in no particular order.
*Source: Coherent Market Insights
setting-icon
Want to purchase customized report?
please let us know !

Global Fragment Based Drug Discovery Market Analysis

The Global Fragment Based Drug Discovery Market is estimated to be valued at USD 1.21 Bn in 2024 and is expected to reach USD 2.60 Bn by 2031, growing at a compound annual growth rate (CAGR) of 11.6% from 2024 to 2031. This significant growth can be attributed to increasing adoption of fragment-based methods over high-throughput screening.

The market is expected to witness notable growth over the forecast period. Increased R&D investments from pharmaceutical companies for drug discovery along with rapid adoption of fragment-based screening over other traditional methods are some key factors driving the market. Additionally, availability of advanced technologies for structural determination and characterization of fragments has propelled the market growth over the years.